ASBP
Aspire Biopharma Holdings, Inc.
NASDAQ · Healthcare · Biotechnology · US
$9.01
−2.59%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 97.7K | 6.2K | — | — | — |
| Cost of Revenue | 79.7K | 6.3K | — | — | — |
| Gross Profit | 17.9K | (116.00) | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 838.1K | 923.9K | 144.4K | 72.0K | — |
| SG&A Expense | 6.2M | 18.4M | 1.1M | 1.3M | 976.3K |
| General & Admin Expense | 3.2M | 17.6M | 940.4K | 1.3M | — |
| Selling & Marketing Expense | 853.4K | 789.8K | 126.1K | — | — |
| Other Expenses | 42.4K | — | — | (72.0K) | — |
| Total Operating Expenses | 7.1M | 19.4M | 1.2M | 1.3M | 976.3K |
| Cost and Expenses | 7.2M | 19.4M | 1.2M | 1.3M | 976.3K |
| Operating Income (EBIT) | (7.1M) | (19.4M) | (1.2M) | (1.3M) | (976.3K) |
| Non-Operating | |||||
| Interest Income | 61.7K | — | 548.7K | 5.8M | 4.3M |
| Interest Expense | 9.3M | 8.5M | 98.0K | 9.0K | — |
| Net Interest Income | (9.2M) | (8.5M) | 450.7K | 5.8M | 4.3M |
| Other Non-Op Income/Expense | (4.0M) | (5.1M) | (98.0K) | 5.8M | 4.3M |
| Non-Operating Income (excl Interest) | (775.1K) | — | — | (5.8M) | — |
| EBT (Pre-Tax Income) | (11.0M) | (24.5M) | (1.3M) | 4.5M | 3.3M |
| Income Tax Expense | — | — | 1.0K | — | — |
| Bottom Line | |||||
| Net Income | (11.0M) | (24.5M) | (1.3M) | 4.5M | 3.3M |
| Earnings from Cont. Ops | (11.0M) | (24.5M) | (1.3M) | 4.5M | 3.3M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (11.0M) | (24.5M) | (1.3M) | 4.5M | 3.3M |
| Per Share | |||||
| Basic EPS | ($8.02) | ($16.38) | ($34.17) | $9.31 | $3.72 |
| Diluted EPS | ($8.02) | ($16.38) | ($34.17) | $9.31 | $3.72 |
| Revenue Per Share | $0.09 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 1.0M | 1.5M | 38339 | 479478 | 898437 |
| Diluted Shares Outstanding | 1.0M | 1.5M | 38339 | 479478 | 898437 |
| Profitability Metrics | |||||
| EBITDA | 3.3M | (11.3M) | (1.2M) | 5.8M | (976.3K) |
| D&A | 9.6M | 8.0M | — | 1.3M | — |
| EBIT | (6.3M) | (19.4M) | (1.2M) | 4.5M | (976.3K) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026